<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967329</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007868</org_study_id>
    <nct_id>NCT01967329</nct_id>
  </id_info>
  <brief_title>CANHelp Working Group Treatment Trials</brief_title>
  <official_title>Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Innovates Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ArcticNet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CANHelp Working Group Treatment Trials are part of a comprehensive research program&#xD;
      carried out by the Canadian North Helicobacter pylori (CANHelp) Working Group. The treatment&#xD;
      component involves a series of community-specific trials designed with community input and&#xD;
      varying on the specific treatment regimens and number of treatment arms among other study&#xD;
      details.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CANHelp Working Group is a collaborative team that links University of Alberta&#xD;
      researchers with Canadian northern community leaders and health officials in a collaborative&#xD;
      effort to investigate H. pylori infection with the goal of finding solutions to community&#xD;
      concerns about health risks. The research program uses a community-driven research approach&#xD;
      in northern communities to characterize the burden of disease from H. pylori infection and&#xD;
      exchange knowledge with community members and decision makers to identify ways to reduce&#xD;
      health risks from this infection.&#xD;
&#xD;
      For the participating communities, the treatment trials aim to:&#xD;
&#xD;
        1. Estimate the effectiveness of alternate H. pylori treatment regimens to identify optimal&#xD;
           regimens for the local setting&#xD;
&#xD;
        2. Identify factors external to the treatment regimen that influence short- and long-term&#xD;
           treatment success&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-treatment H. pylori status by urea breath test</measure>
    <time_frame>A minimum of 10 weeks after participant has completed treatment</time_frame>
    <description>Treatment effectiveness, defined as the probability (average risk) of elimination of H. pylori infection following treatment, measured as the proportion of trial participants with a negative post-treatment urea breath test at least 10 weeks following completion of treatment. Using an intention-to-treat analysis, the denominator for this proportion is the number of trial participants assigned treatment. Using a per-protocol analysis, the denominator for this proportion is the number of trial participants who completed treatment and were tested post-treatment.&#xD;
Participants are administered a urea breath test using 13C-labeled urea dissolved in a citric acid solution. We use the following test value classifications for determining the outcome:&#xD;
&gt;=4.0 (Positive for H. pylori infection) Between 2.5 and 4.0 (Borderline; repeat test) Between 2.4 and -1.99 (Negative for H. pylori infection) Less than -2.0 (Uncertain test result, repeat test)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to treatment regimen</measure>
    <time_frame>An expected average of 1 week after treatment is completed</time_frame>
    <description>Participants are asked to return blister packs with unused medication so skipped doses can be counted. Participants are also interviewed to obtain details about their adherence to the regimen.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Frequency of adverse effects</measure>
    <time_frame>From the time treatment is started to an expected average of 1 week after treatment is completed</time_frame>
    <description>Participants are contacted by telephone during the completion of the treatment regimen and asked if they have experienced adverse effects. Participants are also interviewed immediately after the completion of treatment and asked if they experienced adverse effects during the completion of treatment.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Standard Triple, treatment naive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Triple Therapy for H. pylori:&#xD;
Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)&#xD;
One of two treatments randomly assigned to treatment naive participants in Aklavik</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential, treatment naive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sequential Therapy for H. pylori:&#xD;
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)&#xD;
One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk &amp; Fort McPherson</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple, treatment naive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadruple Thearpy for H. pylori:&#xD;
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily&#xD;
One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk &amp; Fort McPherson</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential, previous failure(s)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sequential Therapy for H. pylori:&#xD;
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)&#xD;
One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk &amp; Fort McPherson</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple, previous failure(s)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadruple Therapy for H. pylori:&#xD;
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily&#xD;
One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk &amp; Fort McPherson</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential, clarithromycin-resistant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sequential Therapy for H. pylori:&#xD;
Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)&#xD;
One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadruple, clarithromycin-resistant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Quadruple Therapy for H. pylori:&#xD;
Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily&#xD;
One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Triple</intervention_name>
    <description>Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)</description>
    <arm_group_label>Standard Triple, treatment naive</arm_group_label>
    <other_name>Standard Triple Therapy for H. pylori</other_name>
    <other_name>Hp-PAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sequential</intervention_name>
    <description>Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)</description>
    <arm_group_label>Sequential, clarithromycin-resistant</arm_group_label>
    <arm_group_label>Sequential, previous failure(s)</arm_group_label>
    <arm_group_label>Sequential, treatment naive</arm_group_label>
    <other_name>Sequential Therapy for H. pylori</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadruple</intervention_name>
    <description>Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily</description>
    <arm_group_label>Quadruple, clarithromycin-resistant</arm_group_label>
    <arm_group_label>Quadruple, previous failure(s)</arm_group_label>
    <arm_group_label>Quadruple, treatment naive</arm_group_label>
    <other_name>Quadruple Therapy for H. pylori</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 15 years of age&#xD;
&#xD;
          -  Identified as H. pylori infected with a positive urea breath test and/or biopsy-based&#xD;
             evidence of H. pylori infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to amoxicillin, metronidazole or clarithromycin&#xD;
&#xD;
          -  Antibiotic therapy within 4 weeks prior to randomization&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Severe cardio-respiratory, pulmonary, endocrine, hepatic or renal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Goodman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.canhelpworkinggroup.ca/</url>
    <description>Canadian North Helicobacter pylori (CANHelp) Working Group website</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Karen Goodman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>No plan to make individual participant data (IPD) available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

